These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32017057)

  • 1. Systemic redox imbalance in patients with nonalcoholic fatty liver disease.
    Asghari S; Hamedi-Shahraki S; Amirkhizi F
    Eur J Clin Invest; 2020 Apr; 50(4):e13211. PubMed ID: 32017057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients.
    Świderska M; Maciejczyk M; Zalewska A; Pogorzelska J; Flisiak R; Chabowski A
    Free Radic Res; 2019 Aug; 53(8):841-850. PubMed ID: 31234658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial.
    Asghari S; Rezaei M; Rafraf M; Taghizadeh M; Asghari-Jafarabadi M; Ebadi M
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative Stress and Nonalcoholic Fatty Liver Disease in Hemodialysis Patients.
    Wu PJ; Chen JB; Lee WC; Ng HY; Lien SC; Tsai PY; Wu CH; Lee CT; Chiou TT
    Biomed Res Int; 2018; 2018():3961748. PubMed ID: 30515395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Asghari S; Rafraf M; Farzin L; Asghari-Jafarabadi M; Ghavami SM; Somi MH
    Adv Pharm Bull; 2018 Jun; 8(2):307-317. PubMed ID: 30023333
    [No Abstract]   [Full Text] [Related]  

  • 6. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis.
    Spahis S; Delvin E; Borys JM; Levy E
    Antioxid Redox Signal; 2017 Apr; 26(10):519-541. PubMed ID: 27452109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherogenic changes of low-density lipoprotein susceptibility to oxidation, and antioxidant enzymes in pulmonary tuberculosis.
    Nezami N; Ghorbanihaghjo A; Rashtchizadeh N; Argani H; Tafrishinejad A; Ghorashi S; Hajhosseini B
    Atherosclerosis; 2011 Jul; 217(1):268-73. PubMed ID: 21497814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of the superoxide dismutase by malondialdehyde in the nonalcoholic fatty liver disease: a combined molecular docking approach to clinical studies.
    Arya A; Azarmehr N; Mansourian M; Doustimotlagh AH
    Arch Physiol Biochem; 2021 Dec; 127(6):557-564. PubMed ID: 31475569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease.
    Orem A; Yandi YE; Vanizor B; Cimşit G; Uydu HA; Malkoç M
    Clin Biochem; 2002 May; 35(3):217-24. PubMed ID: 12074830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Samy W; Hassanian MA
    Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss enhances hepatic antioxidant status in a NAFLD model induced by high-fat diet.
    Mendes IKS; Matsuura C; Aguila MB; Daleprane JB; Martins MA; Mury WV; Brunini TMC
    Appl Physiol Nutr Metab; 2018 Jan; 43(1):23-29. PubMed ID: 28834687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease.
    Köroğlu E; Canbakan B; Atay K; Hatemi İ; Tuncer M; Dobrucalı A; Sonsuz A; Gültepe I; Şentürk H
    Turk J Gastroenterol; 2016 Jul; 27(4):361-6. PubMed ID: 27458852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol inhibits nonalcoholic fatty liver disease in rats.
    Bujanda L; Hijona E; Larzabal M; Beraza M; Aldazabal P; García-Urkia N; Sarasqueta C; Cosme A; Irastorza B; González A; Arenas JI
    BMC Gastroenterol; 2008 Sep; 8():40. PubMed ID: 18782455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of 12 week-maximum fat oxidation intensity (FATmax) exercise on microvascular function in obese patients with nonalcoholic fatty liver disease and its mechanism.
    Yang R; Wan L; Zhu H; Peng Y
    Gen Physiol Biophys; 2023 May; 42(3):251-262. PubMed ID: 37098738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease.
    Liu W; Baker SS; Baker RD; Zhu L
    Curr Drug Targets; 2015; 16(12):1301-14. PubMed ID: 25915484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis.
    Kumar A; Sharma A; Duseja A; Das A; Dhiman RK; Chawla YK; Kohli KK; Bhansali A
    J Clin Exp Hepatol; 2013 Mar; 3(1):12-8. PubMed ID: 25755466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease.
    Perlemuter G; Davit-Spraul A; Cosson C; Conti M; Bigorgne A; Paradis V; Corre MP; Prat L; Kuoch V; Basdevant A; Pelletier G; Oppert JM; Buffet C
    Liver Int; 2005 Oct; 25(5):946-53. PubMed ID: 16162151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Decreased Response to Resistin in Mononuclear Leukocytes Contributes to Oxidative Stress in Nonalcoholic Fatty Liver Disease.
    Garcia CC; Piotrkowski B; Baz P; Poncino D; Benavides J; Colombato L; Toso MLR; Yantorno S; Descalzi V; Gondolesi GE; Fraga CG; Cherñavsky AC
    Dig Dis Sci; 2022 Jul; 67(7):3006-3016. PubMed ID: 34156590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.